Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Friday, November 30, 2018
Onco360 announced it was selected as a specialty pharmacy network partner for Astellas’ new product Xospata (gilteritinib).
read more
Onco360® announced it has been selected as a specialty pharmacy network partner for Karyopharm’s new product XPOVIO™ (selinexor).
read more
Oncobiologics has entered into a MSA with Sonnet BioTherapeutics, a privately held development stage biopharmaceutical company, and has officially launched its BioSymphony Platform.
read more
Wednesday, November 07, 2018
Oncodesign announced a service partnership with Galderma, a dermatological unit belonging to Nestlé Skin Health.
read more
Oncodesign has formed a new strategic alliance with HitGen, a Chinese biotech company.
read more
Thursday, January 25, 2024
Oncodesign Services (ODS), a Contract Research Organization specialized in drug discovery and preclinical services, announces its acquisition of ZoBio, a Dutch CRO expert in biophysics-based small molecule drug discovery.
read more
Oncodesign Services and Veritas In Silico Inc have entered into a Memorandum of Understanding (“MOU”) to respond to the needs of pharmaceutical companies seeking to develop innovative small molecule drugs targeting messenger RNA (“mRNA”).
read more
Oncodesign Services, a Contract Research Organization (CRO) specialized in drug discovery and preclinical services in oncology and immuno-inflammation, announced the execution of a Preclinical License and Supply Agreement
read more
Oncodesign Services has appointed Dr. Aidan Synnott as chief executive officer, to help strengthen its position as a trusted partner in drug discovery. The appointment reflects the company’s commitment to deepen client collaboration, enhance the ...
read more
Oncodesign Services has extended its collaboration with GIP ARRONAX to secure access to astatine-211 (At-211) as well as other radionuclides used in targeted radiotherapy (TRT), supporting the advancement of discovery and preclinical programs.
read more
Oncodesign and HitGen announced the start of a worldwide strategic alliance in Integrated Drug Discovery Services for the identification and progression of new chemical entities.
read more
Thursday, November 21, 2019
Onconova have entered into a Distribution, License and Supply Agreement with Knight Therapeutics will have the exclusive rights to commercialize rigosertib in Canada.
read more
Wednesday, November 17, 2021
OncoOne, a biotechnology company focused on discovering precision medicines for cancer and other indications and GenScript ProBio, a leading CDMO in biologics and gene cell therapy, today announced that the companies have entered into an agreement ...
read more
Wednesday, January 06, 2021
Oncorus has signed a 15-year lease to build an 88,000 square foot GMP viral immunotherapy clinical manufacturing facility in Andover, Massachusetts.
read more
OncoSec has entered into a research collaboration agreement with the University of California, Los Angeles on behalf of Roger S. Lo, M.D., Ph.D. and his research team
read more